Nitric oxide and portal hypertension: Its role in the regulation of intrahepatic and splanchnic vascular resistance

Seminars in Liver Disease

Volumn 19, Issue 4, 1999, Pages 411-426

  Wiest, Reiner ^a,b   Groszmann, Roberto J ^a,b  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b VA CONNECTICUT HEALTHCARE SYSTEM   (United States)

Author keywords

Hyperdynamic circulation; Liver cirrhosis; Nitric oxide; Portal hypertension

Indexed keywords

NITRIC OXIDE;

ARTICLE; BLOOD VESSEL TONE; HEMODYNAMICS; LIVER BLOOD FLOW; LIVER CIRCULATION; LIVER CIRRHOSIS; PATHOPHYSIOLOGY; PORTAL HYPERTENSION; PRIORITY JOURNAL; SPLANCHNIC BLOOD FLOW; VASODILATATION;

EID: 0033427391     PISSN: 02728087     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2007-1007129     Document Type: Article

References (201)

1. Moncada S, Palmer RM, Higgs EA. Nitric oxide: Physiology, pathophysiology, and pharmacology. Pharmacol Rev 1991;43: 109-142
2. Vanhoutte PM. Endothelium and control of vascular function. State of the Art lecture. Hypertension 1989;13:658-667
3. Mittal MK, Gupta TK, Lee FY, Sieber CC, Groszmann RJ. Nitric oxide modulates hepatic vascular tone in normal rat liver. Am J Physiol 1994;267:G416-G422
4. Raij L. Hypertension, endothelium, and cardiovascular risk factors. Am J Med 1991;90(2A):13S-18S
5. Dusting GJ. Nitric oxide in cardiovascular disorders. J Vasc Res 1995;32:143-161
6. Busse R, Fleming I. Endothelial dysfunction in atherosclerosis. J Vasc Res 1996;33:181-194
7. Gupta TK TM, Chung MK. Endothelial dysfunction in the intrahepatic microcirculation of cirrhotic rats. Hepatology 1998;28: 926-931
8. Sessa WC. The nitric oxide synthase family of proteins. J Vasc Res 1994;31:131-143
9. Takahashi M, Ishida T, Traub O, Corson MA, Berk BC. Mechanotransduction in endothelial cells: Temporal signaling events in response to shear stress. J Vasc Res 1997;34:212-219
10. Sessa WC, Garcia-Cardena G, Liu J, et al. The Golgi association of endothelial nitric oxide synthase is necessary for the efficient synthesis of nitric oxide. J Biol Chem 1995;270: 17641-17644
11. Nathan C, Xie QW. Regulation of biosynthesis of nitric oxide. J Biol Chem 1994;269:13725-13728
12. Michel JB, Feron O, Sase K, Prabhaker P, Michel T. Caveolin versus calmodulin. Counterbalancing allosteric modulators of endothelial nitric oxide synthase. J Biol Chem 1997;272:25907-25912
13. Garcia-Cardena G, Fan R, Shah V, et al. Dynamic activation of endothelial nitric oxide synthase by Hsp90. Nature 1998;392: 821-824
14. Garcia-Cardena G, Fan R, Stern DF, Liu J, Sessa WC. Endothelial nitric oxide synthase is regulated by tyrosine phosphorylation and interacts with caveolin-1. J Biol Chem 1996;271: 27237-27240
15. Garcia-Cardena G, Martasek P, Masters BS, et al. Dissecting the interaction between nitric oxide synthase (NOS) and caveolin. J Biol Chem 1997;41:25437-25440
16. Buga GM, Gold ME, Fukuto JM, Ignarro LJ. Shear stress-induced release of nitric oxide from endothelial cells grown on beads. Hypertension 1991;17:187-193
17. Rubanyi GM, Romero JC, Vanhoutte PM. Flow-induced release of endothelium-derived relaxing factor. Am J Physiol 1986;250: H1145-H1149
18. Zimmerman H, Kurzen P, Klossner W, Renner EL, Marti U. Decreased constitutive hepatic nitric oxide synthase expression in secondary biliary fibrosis and its changes after Roux-Y choledocho-jejunostomiy in the rat. J Hepatol 1996;25:567-573
19. Rockey DC, Chung JJ. Reduced nitric oxide production by endothelial cells in cirrhotic rat liver: Endothelial dysfunction in portal hypertension. Gastroenterology 1998;14:344-351
20. Shah V, Toruner M, Haddad F, et al. Impaired activity associated with enhanced caveolin binding to endotheliol nitric oxide synthase in experimental liver cirrhosis. Gastroenterology (In press)
21. Greenway CV, Stark RD. Hepatic vascular bed. Physiol Rev 1971;51:23-65
22. Beker S, Valencia-Parparcen J. Portal hypertension syndrome. A comparative analysis of bilharzial fibrosis and hepatic cirrhosis. Am J Dig Dis 1968;13:1047-1054
23. Blendis LM, Orrego H, Crossley IR, Blake JE, Medline A. Israel Y. The role of hepatocyte enlargement in hepatic pressure in cirrhotic and noncirrhotic alcoholic liver disease. Hepatology 1982;2:539-546
24. Reynolds TB, Hidemura R, Michel H, Peters R. Portal hypertension without cirrhosis in alcoholic liver disease. Ann Intern Med 1969;70:497-506
25. Reynolds TB, Edmonson HA. Alcoholic hepatitis. Ann Intern Med 1971;74:441-442
26. Schaffner F, Popper H. Capillarization of the hepatic sinusoids in man. Gastroenterology 1963;44:239-251
27. Boyer TD, Triger DR, Horisawa M, Redeker AG, Reynolds TB. Direct transhepatic measurement of portal vein pressure using a thin needle. Comparison with wedged hepatic vein pressure. Gastroenterology 1977;72:584-589
28. Pomier-Layrargues G, Kusizelewicz D, Willems B, et al. Presinusoidal portal hypertension in non-alcoholic cirrhosis. Hepatology 1985;5:415-418
29. van Leeuwen DJ, Howe SC, Scheuer PJ, Sherlock S. Portal hypertension in chronic hepatitis: Relationship to morphological changes. Gut 1990;31:339-343
30. Bhathal PS, Grossman HJ. Reduction of the increased portal vascular resistance of the isolated perfused cirrhotic rat liver by vasodilators. J Hepatol 1985;1:325-337
31. Reichen J, Le M. Verapamil favorably influences hepatic microvascular exchange and function in rats with cirrhosis of the liver. J Clin Invest 1986;78:448-455
32. McCuskey RS, Reilly FD. Hepatic microvasculature: Dynamic structure and its regulation. Semin Liver Dis 1993;13:1-12
33. Nakata K, Leong GF, Brauer RW. Direct measurement of blood pressures in minute vessels of the liver. Am J Physiol 1960; 199:1181-1188
34. Zhang JX, Pegoli W Jr, Clemens MG. Endothelin-1 induces direct constriction of hepatic sinusoids. Am J Physiol 1994;226: G624-G632
35. McCuskey RS. A dynamic and static study of hepatic arterioles and hepatic sphincters. Am J Anat 1966;119:455-477
36. McCuskey RS. The hepatic microvascular system. In: Arias IM, ed. The Liver, Biology and Pathobiology. New York: Raven Press, 1994, pp 1089-1106
37. Wake K. Perisinusoidal fat-storing cells of the liver. In: Surrenti C, Casini A, Milani S, Pinzani M, eds. Fat-Storing Cells in Liver Fibrosis. Dordrecht: Kluwer, 1994, pp 1-10
38. Sims DE. The pericyte - a review. Tissue Cell 1986;18:153-174
39. Pinzani M, Failli P, Ruocco C, et al. Fat-storing cells as liverspecific pericytes. Spatial dynamics of agonist-stimulated intracellular calcium transients. J Clin Invest 1992;90:642-646
40. Bauer M, Zhang JX, Bauer I, Clemens MG. ET-1 induced alterations of hepatic microcirculation: Sinusoidal and extrasinusoidal sites of action. Am J Physiol 1994;267:G143-G149
41. Rockey DC, Weisiger RA. Endothelin induced contractility of stellate cells from normal and cirrhotic rat liver: Implications for regulation of portal pressure and resistance. Hepatology 1996;24:233-240
42. Rockey DC, Boyles JK, Gabbiani G, Friedman SL. Rat hepatic lipocytes express smooth muscle actin upon activation in vivo and in culture. J Submicrosc Cytol Pathol 1992;24:193-203
43. Housset CN, Rockey DC, Friedman SL, Bissell DM. Hepatic lipocytes: A major target for endothelin-1. J Hepatol 1995; 22:55-60
44. Rudolph R, McClure WJ, Woodward M,.Contractile fibroblasts in chronic alcoholic cirrhosis. Gastroenterology 1979;76:704-709
45. Suematsu M, Goda N, Sano T, et al. Carbon monoxide: An endogenous modulator of sinusoidal tone in the perfused rat liver. J Clin Invest 1995;96:2431-2437
46. Kawada N, Tran-Thi TA, Klein H, Decker K. The contraction of hepatic stellate (Ito) cells stimulated with vasoactive substances. Possible involvement of endothelin 1 and nitric oxide in the regulation of the sinusoidal tonus. Eur J Biochem 1993;213:815-823
47. Sakamoto M, Ueno T, Kin M, et al. Ito cell contraction in response to endothelin-1 and substance P. Hepatology 1993;18:978-983
48. Bataller R, Nicolas JM, Gines P, et al. Arginine vasopressin induces contraction and stimulates growth of cultured human hepatic stellate cells. Gastroenterology 1997;113:615-624
49. Housset C, Rockey DC, Bissell DM. Endothelin receptors in rat liver: Lipocytes as a contractile target for endothelin 1. Proc Natl Acad Sci USA 1993;90:9266-9270
50. Yanagisawa M, Kurihara H, Kimura S, et al. A novel potent vasoconstrictor peptide produced by vascular endothelial cells. Nature 1988;332:411-415
51. Lüscher TF, Boulanger CM, Dohi Y, Yang ZH. Endothelium-derived contracting factors. Hypertension 1992;19:117-130
52. Sokolovsky M. Endothelin receptor subtypes and their role in transmembrane signaling mechanisms. Pharmacol Ther 1995; 68:435-471
53. B receptors mediate vascular smooth muscle contraction. Br J Pharmacol 1992;107:858-860
54. Webb DJ, Monge JC, Rabelink TJ, Yanagisawa M. Endothelin: New discoveries and rapid progress in the clinic. Trends Pharmacol Sci 1998;19:5-8
55. Stephenson K, Gupta A, Mustafa SB, Halff GA. Endothelin-stimulated nitric oxide production in the isolated Kupffer cell. J Surg Res 1997;73:149-154
56. Oshita M, Takei Y, Kawano S, et al. Roles of endothelin-1 and nitric oxide in the mechanism for ethanol-induced vasoconstriction in rat liver. J Clin Invest 1993;91:1337-1342
57. Okumura S, Takei Y, Kawano S, et al. Vasoactive effect of endothelin-1 on rat liver in vivo. Hepatology 1994;19:155-161
58. Gandhi CR, Stephenson K, Olson MS. Endothelin, a potent peptide agonist in the liver. J Biol Chem 1990;265:17432-17435
59. Kaneda K, Ekataksin W, Sogawa M, Matsumura A, Cho A, Kawada N. Endothelin-1-induced vasoconstriction causes a significant increase in portal pressure of rat liver: Localized constrictive effect on the distal segment of preterminal portal venules as revealed by light and electron microscopy and serial reconstruction. Hepatology 1998;27:735-747
60. Reichen J, Gerbes AL, Steiner MJ, Sagesser H, Clozel M. The effect of endothelin and its antagonist bosentan on hemodynamics and microvascular exchange in cirrhotic rat liver. J Hepatol 1998;28:1020-1030
61. Sogni P, Moreau R, Gomola A, et al. Beneficial hemodynamic effects of bosentan, a mixed ET(A) and ET(B) receptor antagonist, in portal hypertensive rats. Hepatology 1998;28:655-659
62. Gandhi CR, Nemoto EM, Watkins SC, Subbotin VM. An endothelin receptor antagonist TAK 044 ameliorates carbon-tetrachloride induced acute liver injury and portal hypertension in rats. Liver 1998;18:39-48
63. Moller S, Gülberg V, Henriksen JH, Gerbes AL. Endothelin-1 and endothelin-3 in cirrhosis: Relations to systemic and splanchnic haemodynamics. J Hepatol 1995;23:135-144
64. Gülberg V, Gerbes AL, Vollmar AM, Paumgartner G. Endothelin-3 like immunoreactivity in plasma of patients with cirrhosis of the liver. Life Sci 1992;51:1165-1169
65. Leivas A, Jimenez W, Lamas S, et al. Endothelin 1 does not play a major role in the homeostasis of arterial pressure in cirrhotic rats with ascites. Gastroenterology 1995;108:1842-1848
66. Gerbes AL, Moller S, Gülberg V, Henriksen JH. Endothelin-1 and -3 plasma concentrations in patients with cirrhosis: Role of splanchnic and renal passage and liver function. Hepatology 1995;21:735-739
67. Pinzani M, Milani S, De Franco R, et al. Endothelin 1 is overexpressed in human cirrhotic liver and exerts multiple effects on activated stellate cells. Gastroenterology 1996;110:534-548
68. Leivas A, Jimenez W, Bruix J, et al. Gene expression of endothelin-1 and ETa and ETb receptors in human cirrhosis: Relationship with hepatic hemodynamics. J Vasc Res 1998;35:186-193
69. Gandhi CR, Sproat LA, Subbotin VM. Increased hepatic endothelin-1 levels and endothelin receptor density in cirrhotic rats. Life Sci 1996;58:55-62
70. 125I-endothelin to fat-storing cells in rat liver revealed by electron microscopic radioautography. Anat Embryol 1992;185:97-100
71. Orrego H, Blendis LM, Crossley IR, et al. Correlation of intrahepatic pressure with collagen in the Disse space and hepatomegaly in humans and in the rat. Gastroenterology 1981; 80:546-556
72. Bauer M, Paquette NC, Zhang JX, et al. Chronic ethanol consumption increases hepatic sinusoidal contractile response to endothelin-1 in the rat. Hepatology 1995;22:1565-1576
73. Poo JL, Jimenez S, Munoz RM, et al. Chronic blockade of endothelin receptors in cirrhotic rats: Hepatic and hemodynamic effects. Gastroenterology 1999;116:161-167
74. Rockey DC, Chung JJ. Inducible nitric oxide synthase in rat hepatic lipocytes and the effect of nitric oxide on lipocyte contractility. J Clin Invest 1995;95:1199-1206
75. Tran-Thi TA, Kawada N, Decker K. Regulation of endothelin-1 action on the perfused rat liver. FEBS Lett 1993;318:353-357
76. Boulanger C, Lüscher TF. Release of endothelin from the porcine aorta. Inhibition by endothelium-derived nitric oxide. J Clin Invest 1990;85:587-590
77. Rubanyi GM. Endothelium-derived relaxing and contracting factors. J Cell Biochem 1991;46:27-36
78. Vane JR, Anggard EE, Botting RM. Regulatory functions of the vascular endothelium. N Engl J Med 1990;323:27-36
79. Shah V, Haddad FG, Garcia-Cardena G, et al. Liver sinusoidal endothelial cells are responsible for nitric oxide modulation of resistance in the hepatic sinusoids. J Clin Invest 1997;100: 2923-2930
80. Ludmer PL, Selwyn AP, Shook TL, et al. Paradoxical vasoconstriction induced by acetylcholine in atherosclerotic coronary arteries. N Engl J Med 1986;315:1046-1051
81. Conraads VM, Bosman JM, Clayes MJ, et al. Paradoxic pulmonary vasoconstriction in response to acetylcholine in patients with pulmonary hypertension. Chest 1994;106:385-390
82. Kuchan MJ, Frangos JA. Role of calcium and calmodulin in flow-induced nitric oxide production in endothelial cells. Am J Physiol 1994;266:C628-C636
83. Ranjan V, Xiao Z, Diamond SL. Constitutive NOS expression in cultured endothelial cells is elevated by fluid shear stress. Am J Physiol 1995;269:H550-H555
84. Radomski MW, Palmer RMJ, Moncada S. An L-arginine/nitric oxide pathway present in human platelets regulates aggregation. Proc Natl Acad Sci USA 1990;87:5193-5197
85. Diodati JG, Dakak N, Gilligan DM, Quyyumi AA. Effect of atherosclerosis on endothelium-dependent inhibition of platelet activation in humans. Circulation 1998;98:17-24
86. Wanless IR, Wong F, Blendis LM, Greig P, Heathcote EJ, Levy G. Hepatic and portal vein thrombosis in cirrhosis: Possible role in development of parenchymal extinction and portal hypertension. Hepatology 1995;21:1238-1247
87. Myers PR, Tanner MA. Vascular endothelial cell regulation of extracellular matrix collagen: Role of nitric oxide. Arterioscler Thromb Vasc Biol 1998;18:717-722
88. Muriel P. Nitric oxide protection of rat liver form lipid peroxidation, collagen accumulation, and liver damage induced by carbon tetrachloride. Biochem Pharmacol 1998;56:773
89. Kubes P, Suzuki M, Ganger DN. Nitric oxide: An endogenous modulator of leukocyte adhesion. Proc Natl Acad Sci USA 1991;88:4651-4655
90. Böger RH, Bode-Böger SM, Frölich JC. The L-arginine-nitric oxide pathway: Role in atherosclerosis and therapeutic implications. Atherosclerosis 1996;127:1-11
91. Keaney JF, Vita JA. Atherosclerosis, oxidative stress, and antioxidant protection in endothelium-derived relaxing factor action. Prog Cardiovasc Dis 1995;38:129-154
92. Clancy RM, Leszczynska-Piziak J, Abramson SB. Nitric oxide, an endothelial cell relaxation factor, inhibits neurophil superoxide anion production via a direct action on the NADPH oxidase, J Clin Invest 1992;90:1116-1121
93. 2+-calmodulin and caveolin. J Biol Chem 1997;272:15583-15586
94. Vorobioff J, Bredfeldt JE, Groszmann RJ. Increased blood flow through the portal system in cirrhotic rats. Gastroenterology 1984;87:1120-1126
95. Groszmann RJ. Hyperdynamic circulation of liver disease 40 years later: Pathophysiology and clinical consequences. Hepatology 1994;20:1359-1363
96. Kotelanski B, Groszmann RJ, Cohn JN. Circulation times in the splanchnic and hepatic beds in alcoholic liver disease. Gastroenterology 1972;63:102-111
97. Colombato LA, Albillos A, Groszmann RJ. Temporal relationship of peripheral vasodilatation, plasma volume expansion and the hyperdynamic circulatory state in portal-hypertensive rats. Hepatology 1992;15:323-328
98. Cohn JN, Khatri IM, Groszmann RJ, Kotelanski B. Hepatic blood flow in alcoholic liver disease measured by an indicator dilution technic. Am J Med 1972;53:704-714
99. Williams R, Condon RE, Williams HS, Blendis LM, Kreel L. Splenic blood flow in cirrhosis and portal hypertension. Clin Sci 1968;34:441-452
100. Sikuler E, Groszmann RJ. Interaction of flow and resistance in maintenance of portal hypertension in a rat model. Am J Physiol 1986;250:G205-G212
101. Vorobioff J, Bredfeldt JE, Groszmann RJ. Hyperdynamic circulation in portal-hypertensive rat model: A primary factor for maintenance of chronic portal hypertension. Am J Physiol 1983;244:G52-G57
102. Sikuler E, Kravetz D, Groszmann RJ. Evolution of portal hypertension and mechanisms involved in its maintenance in a rat model. Am J Physiol 1985;248:G618-G625
103. Pizcueta P, Pique JM, Fernandez M, et al. Modulation of the hyperdynamic circulation of cirrhotic rats by nitric oxide inhibition. Gastroenterology 1992;103:1909-1915
104. Pizcueta MP, Pique JM, Bosch J, Whittle BJ, Moncada S. Effects of inhibiting nitric oxide biosynthesis on the systemic and splanchnic circulation of rats with portal hypertension. Br J Pharmacol 1992;105:184-190
105. Casadevall M, Pique JM, Cirera I, et al. Increased blood hemoglobin attenuates splanchnic vasodilation in portal-hypertensive rats by nitric oxide inactivation. Gastroenterology 1996;110: 1156-1165
106. Kiel JW, Pitts V, Benoit JN, Granger DN, Shepherd AP. Reduced vascular sensitivity to norepinephrine in portal-hypertensive rats. Am J Physiol 1985;248:G192-G195
107. Sieber CC, Groszmann RJ. Nitric oxide mediates hyporeactivity to vasopressors in mesenteric vessels of portal hypertensive rats. Gastroenterology 1992;103:235-239
108. Sieber CC, Groszmann RJ. In vitro hyporeactivity to methoxamine in portal hypertensive rats: Reversal by nitric oxide blockade. Am J Physiol 1992;262:G996-G1001
109. Hartleb M, Moreau R, Cailmail S, Gaudin C, Lebrec D. Vascular hyporesponsiveness to endothelin 1 in rats with cirrhosis. Gastroenterology 1994;107:1085-1093
110. Murray BM, Paller MS. Decreased pressor reactivity to angiotensin II in cirrhotic rats. Evidence for a postreceptor defect in angiotensin action. Circ Res 1985;57:424-431
111. Liao JF, Yu PC, Lin HC, Lee FY, Kuo JS, Yang MC. Study on the vascular reactivity and alpha 1-adrenoceptors of portal hypertensive rats. Br J Pharmacol 1994;111:439-444
112. Sieber CC, Lopez-Talavera JC, Groszmann RJ. Role of nitric oxide in the in vitro splanchnic vascular hyporeactivity in ascitic cirrhotic rats. Gastroenterology 1993;104:1750-1754
113. Sieber CC, Sumanovski LT, Moll-Kaufmann C, Stalder GA. Hyposensitivity to nerve stimulation in portal hypertensive rats: Role of nitric oxide. Eur J Clin Invest 1997;27:902-907
114. Atucha NM, Shah V, Garcia-Cardena G, Sessa WE. Groszmann RJ. Role of endothelium in the abnormal response of mesenteric vessels in rats with portal hypertension and liver cirrhosis. Gastroenterology 1996;111:1627-1632
115. Murad F. Cyclic guanosine monophosphate as a mediator of vasodilation. J Clin Invest 1986;78:1-5
116. Cahill PA, Redmond EM, Hodges R, Zhang S, Sitzmann JV. Increaesd endothelial nitric oxide synthase activity in the hyperemic vessels of portal hypertensive rats. J Hepatol 1996; 25:370-378
117. Ros J, Jimenez W, Lamas S, et al. Nitric oxide production in arterial vessels of cirrhotic rats. Hepatology 1995;21:554-560
118. Bolotina VM, Najibi S, Palacino JJ, Pagano PJ, Cohen RA. Nitric oxide directly activates calcium-dependent potassium channels in vascular smooth muscle. Nature 1994;368:850-853
119. Atucha NM, Ortiz MC, Fortepiani LA, Ruiz FM, Martinez C, Garcia-Estan J. Role of cGMP and K-channels as mediators of the mesenteric vascular hyporesponsiveness in portal hypertensive rats. Hepatology 1998;27:900-905
120. Wiest R, Hori N, Cadelina G, Das S, Groszmann RJ. Increased nitric oxide release in response to vasoconstrictors in the superior mesenteric arterial bed of cirrhotic rats. Hepatology 1997; 26:390A
121. Battista S, Bar F, Mengozzo G, Zanon E, Grosso M, Molino G. Hyperdynamic circulation in patients with cirrhosis: Direct measurement of nitric oxide levels in hepatic and portal veins. J Hepatol 1997;26:75-80
122. Smiesko V, Kozik J, Dolezel S. Role of endothelium in the control of arterial diameter by blood flow. Blood Vessels 1985; 22:247-251
123. Sessa WC, Pritchard K, Seyedi N, Wang J, Hintze TH. Chronic exercise in dogs increases coronary vascular nitric oxide production and endothelial cell nitric oxide synthase gene expression. Circ Res 1994;74:349-353
124. Nadaud S, Philippe M, Arnal JF, Michel JB, Soubrier F. Sustained increase in aortic endothelial nitric oxide synthase expression in vivo in a model of chronic high blood flow. Circ Res 1996;9:857-863
125. Martin PY, Ohara M, Gines P, et al. Nitric oxide synthase (NOS) inhibition for one week improves renal sodium and water excretion in cirrhotic rats with ascites. J Clin Invest 1998;101:235-242
126. Martin PY, Xu DL, Niederberger M, et al. Upregulation of endothelial constitutive NOS: A major role in the increased NO production in cirrhotic rats. Am J Physiol 1996;270:F494-F499
127. Niederberger M, Gines P, Martin PY, et al. Comparison of vascular nitric oxide production and systemic hemodynamics in cirrhosis versus prehepatic portal hypertension in rats. Hepatology 1996;24:947-951
128. Cahill PA, Foster C, Redmond EM, Gingalewski C, Wu Y, Sitzmann JV. Enhanced nitric oxide synthase activity in portal hypertensive rabbits. Hepatology 1995;22:598-606
129. Hori N, Wiest R, Groszmann RJ. Enhanced release of nitric oxide in response to changes in flow and shear stress in the superior mesenteric arteries of portal hypertensive rats. Hepatology 1998;28:1467-1473
130. Wiest R, Shah V, Sessa WC, Groszmann RJ. Nitric oxide overproduction by eNOS precedes hyperdynamic splanchnic circulation in portal hypertensive rats. Am J Physiol 1999;276:43-51
131. Lin RS, Lee FY, Lee SD, et al. Endotoxemia in patients with chronic liver diseases: Relationship to severity of liver diseases, presence of esophageal varices, and hyperdynamic circulation. J Hepatol 1995;22:165-172
132. Lee FY, Wang SS, Yang MC, et al. Role of endotoxaemia in hyperdynamic circulation in rats with extrahepatic or intrahepatic portal hypertension. J Gastroenterol Hepatol 1996;11:152-158
133. Lumsden AB, Henderson JM, Kutner MH. Endotoxin levels measured by a chromogenic assay in portal, hepatic and peripheral venous blood in patiens with cirrhosis. Hepatology 1988;8:232-236
134. Kilbourn RG, Belloni P. Endothelial cell production of nitrogen oxides in response to interferon gamma in combination with tumor necrosis factor, interleukin-1, or endotoxin. J Natl Cancer Inst 1990;82:772-776
135. Vallance P, Monrada S. Hyperdynamic circulation in cirrhosis: A role for nitric oxide? Lancet 1991;337;776-778
136. Morales-Ruiz M, Jimenez W, Perez-Sala D, et al. Increased nitric oxide synthase expression in arterial vessels of cirrhotic rats with ascites. Hepatology 1996;24:1481-1486
137. Fernandez M, Garcia-Pagan JC, Casadevall M, et al. Evidence against a role for inducible nitric oxide synthase in the hyperdynamic circulation of portal-hypertensive rats. Gastroenterology 1995;108:1487-1495
138. Heinemann A, Stauber RE. The role of inducible nitric oxide synthase in vascular hyporeactivity of endotoxin-treated and portal hypertensive rats. Eur J Pharmacol 1995;278:87-90
139. Guarner C, Soriano G, Tomas A, et al. Increased serum nitrite and nitrate levels in patients with cirrhosis: Relationship to endotoxemia. Hepatology 1993;18:1139-1143
140. Chu CJ, Lee FY, Wang SS, et al. Hyperdynamic circulation of cirrhotic rats with ascites: Role of endotoxin, tumor necrosis factor-alpha and nitric oxide. Clin Sci 1997;93:219-225
141. Wiest R, Garcia-Tsao G, Cadelina G, Das S, Shah V, Groszmann RJ. Bacterial translocation to mesenteric lymph nodes impairs vascular contractility in superior mesenteric arteries of cirrhotic rats. Hepatology 1998;28:168A
142. Old LJ. Tumor necrosis factor (TNF). Science 1985;230: 630-632
143. Lopez-Talavera JC, Merrill WW, Groszmann RJ. Tumor necrosis factor alpha: A major contributor to the hyperdynamic circulation in prehepatic portal-hypertensive rats. Gastroenterology 1995;108:761-767
144. Lopez-Talavera JC, Cadelina G, Olchowski J, Merrill W, Groszmann RJ. Thalidomide inhibits tumor necrosis factor alpha, decreases nitric oxide synthesis, and ameliorates the hyperdynamic circulatory syndrome in portal-hypertensive rats. Hepatology 1996;23:1616-1621
145. Groszmann RJ, DeFranchis. Portal hypertension. In: Schiff LSE, ed. Diseases of the Liver. Philadelphia: Lippincott Raven, 1998
146. Reichen J. Liver function and pharmacological considerations in pathogenesis and treatment of portal hypertension. Hepatology 1990;11;1066-1078
147. Kravetz D, Arderiu M, Bosch J, et al. Hyperglucagonemia and hyperkinetic circulation after portocaval shunt in the rat. Am J Physiol 1987;252:G257-G261
148. Bernadich C, Bandi JC, Piera C, Bosch J, Rodes J. Circulatory effects of graded diversion of portal blood flow to the systemic circulation in rats: Role of nitric oxide. Hepatology 1997;26: 262-267
149. Sarin SK, Groszmann RJ, Mosca PG, et al. Propranolol ameliorates the development of portal-systemic shunting in a chronic murine schistosomiasis model of portal hypertension. J Clin Invest 1991;87:1032-1036
150. Lin HC, Soubrane O, Lebrec D. Prevention of portal hypertension and portosystemic shunts by early chronic administration of clonidine in conscious portal vein-stenosed rats. Hepatology 1991;14:325-330
151. Halvorsen JF, Myking AO. The porto-systemic collateral pattern in the rat. An angiographic and anatomical study after partial occlusion of the portal vein. Eur Surg Res 1974;6:183-195
152. Lee FY, Colombato LA, Albillos A, Groszmann RJ. Administration of N omega-nitro-L-arginine ameliorates portal-systemic shunting in portal-hypertensive rats. Gastroenterology 1993; 105:1464-1470
153. Mosca P, Lee FY, Kaumann AJ, Groszmann RJ. Pharmacology of portal-systemic collaterals in portal hypertensive rats: Role of endothelium. Am J Physiol 1992;263:G544-G550
154. Ziche M, Morbidelli L, Masini E, et al. Nitric oxide mediates angiogenesis in vivo and endothelial cell growth and migration in vitro promoted by substance P. J Clin Invest 1994;94: 2036-2044
155. Sieber C, Sumanovski LT, Battegay E. Increased role of nitric oxide angiogenesis in chronic portal hypertensive rats. Hepatology 1999;29:1044-1049
156. Awolesi MA, Sessa WC, Sumpio BE. Cyclic strain upregulates nitric oxide synthase in cultured bovine aortic endothelial cells. J Clin Invest 1995;96:1449-1454
157. Geraghty JG, Angerson WJ, Carter DC. Portal venous pressure and portasystemic shunting in experimental portal hypertension. Am J Physiol 1989;257:G52-G57
158. Rudic RD, Shesely EG, Maeda N, Smithies O, Segal SS, Sessa WC. Direct evidence for the importance of endothelium-derived nitric oxide in vascular remodeling. J Clin Invest 1998;101: 731-736
159. Kowalski HJ, Abelman WH. The cardiac output at rest in Laennec cirrhosis. J Clin Invest 1953;32:1025-1033
160. Schlant RC, Tsagaris TS, Robertson RJ. Studies on the acute cardiovascular effects of intravenous sodium nitroprusside. Am J Cardiol 1962;9:51-59
161. Schrier RW, Arroyo V, Bernardi M, Epstein M, Henriksen JH, Rodes J. Peripheral arterial vasodilation hypothesis: A proposal for the initiation of renal sodium and water retention in cirrhosis. Hepatology 1988;8:1151-1157
162. Bernardi M, Trevisani F. Systemic and regional hemodynamics in pre-ascitic cirrhosis. J Hepatol 1997;27:588-591
163. Fernandez-Seara J, Prieto J, Quiroga J, et al. Systemic and regional hemodynamics in patients with liver cirrhosis and ascites with and without functional renal failure. Gastroenterology 1989;97:1304-1312
164. Castro A, Jimenez W, Claria J, et al. Impaired responsiveness to angiotensin II in experimental cirrhosis: Role of nitric oxide. Hepatology 1993;18:367-372
165. Gadano AC, Sogni P, Yang S, et al. Endothelial calcium-calmodulin dependent nitric oxide synthase in the in vitro vascular hyporeactivity of portal hypertensive rats. J Hepatol 1997;26: 678-686
166. Ortiz MC, Fortepiani LA, Martinez C, Atucha NM, Garcia-Estan J. Vascular hyporesponsiveness in aortic rings from cirrhotic rats: Role of nitric oxide and endothelium. Clin Sci (Colch) 1996;91:733-738
167. Weigert AL, Martin PY, Niederberger M, et al. Endothelium-dependent vascular hyporesponsiveness without detection of nitric oxide synthase induction in aortas of cirrhotic rats. Hepatology 1995;22:1856-1862
168. Campillo B, Chabrier PE, Pelle G, et al. Inhibition of nitric oxide synthesis in the forearm arterial bed of patients with advanced cirrhosis. Hepatology 1995;22:1423-1429
169. Claria J, Jimenez W, Ros J, et al. Pathogenesis of arterial hypotension in cirrhotic rats with ascites: Role of endogenous nitric oxide. Hepatology 1992;15:343-349
170. Lee FY, Albillos A, Colombato LA, Groszmann RJ. The role of nitric oxide in the vascular hyporesponsiveness to methoxamine in portal hypertensive rats. Hepatology 1992;16:1043-1048
171. Lee FY, Colombato LA, Albillos A, Groszmann RJ. N omega-nitro-L-arginine administration corrects peripheral vasodilation and systemic capillary hypotension and ameliorates plasma volume expansion and sodium retention in portal hypertensive rats. Hepatology 1993;17:84-90
172. Garcia-Pagan JC, Fernandez M, Bernadich C, et al. Effects of continued NO inhibition on portal hypertensive syndrome after portal vein stenosis in rat. Am J Physiol 1994;267:G984-G990
173. Niederberger M, Martin PY, Gines P, et al. Normalization of nitric oxide production corrects arterial vasodilation and hyperdynamic circulation in cirrhotic rats. Gastroenterology 1995;109: 1624-1630
174. Albillos A, Rossi I. Cacho G, et al. Enhanced endothelium-dependent vasodilation in patients with cirrhosis. Am J Physiol 1995;268:G459-G464
175. Calver A, Harris A, Maxwell JD, Vallance P. Effect of local inhibition of nitric oxide synthesis on forearm blood flow and dorsal hand vein size in patients with alcoholic cirrhosis. Clin Sci 1994;86:203-208
176. Claria J, Jimenez W, Ros J, et al. Increased nitric oxide-dependent vasorelaxation in aortic rings of cirrhotic rats with ascites Hepatology 1994;20:1615-1621
177. Lieberman FL, Ito S, Reynolds TB. Effective plasma volume in cirrhosis with ascites. Evidence that a decreased value does not account for renal sodium retention, a spontaneous reduction in glomerular filtration rate (GFR), and a fall in GFR during drug-induced diuresis. J Clin Invest 1969;48:975-981
178. Maddrey WC, Boyer JL, Sen NN, Thomas J, Basu AK, Iber FL. Plasma volume expansion in portal hypertension. Johns Hopkins Med J 1969;125:171-183
179. Guyton AC, Lindsay AW, Kaufmann B. Effect of mean circulatory filling pressure and other peripheral circulatory factors on cardiac output. Am J Physiol 1955;180:463-468
180. Gines P, Martin PY, Niederberger M. Prognostic significance of renal dysfunction in cirrhosis. Kidney Int 1997;61(suppl): S77-S82
181. Genecin P, Polio J, Grozsmann RJ. Na restriction blunts expansion of plasma volume and ameliorates hyperdynamic circulation in portal hypertension. Am J Physiol 1990;259:G498-G503
182. Colombato LA, Albillos A, Groszmann RJ. The role of central blood volume in the development of sodium retention in portal hypertensive rats. Gastroenterology 1996;110:193-198
183. Epstein M. The Kidney and Liver Disease. Baltimore, MD: Williams & Wilkins, 1988; pp 1-656
184. Schrier RW, De Wardener HE. Tubular reabsorption of sodium ion: Influence of factors other than aldosterone and glomerular filtration rate. N Engl J Med 1971;285:1231-1243
185. Ingles AC, Hernandez I, Garcia-Estan J, Quesada T, Carbonell LF. Limited cardiac preload reserve in conscious cirrhotic rats. Am J Physiol 1991;260:H1912-H1917
186. Atucha NM, Garcia-Estan J, Ramirez A, Perez MC, Quesada T, Romero JC. Renal effects of nitric oxide synthesis inhibition in cirrhotic rats. Am J Physiol 1994;267:R1454-R1460
187. G-monomethyl-L-arginine and L-arginine on acetylcholine renal response. Hypertension 1990;15:659-663
188. Rodriguez-Roisin R, Agusti AG, Roca J. The hepatopulmonary syndrome: New name, old complexities [Editorial]. Thorax 1992;47:897-902
189. Matsumoto A, Ogura K, Hirata Y, et al. Increased nitric oxide in the exhaled air of patients with decompensated liver cirrhosis. Ann Intern Med 1995;123:110-113
190. Sogni P, Gamier P, Gadano A, et al. Endogenous pulmonary nitric oxide production measured from exhaled air is increased in patients with severe cirrhosis. J Hepatol 1995;23:471-473
191. Rolla G, Brussino L, Colagrande P, et al. Exhaled nitric oxide and oxygenation abnormalities in hepatic cirrhosis. Hepatology 1997;26:842-847
192. Cremona G, Higenbottam TW, Mayoral V, et al. Elevated exhaled nitric oxide in patients with hepatopulmonary syndrome. Eur Respir J 1995;8:1883-1885
193. Fallon MB, Abrams GA, Luo B, Hou Z, Daj J, Ku DD. The role of endothelial nitric oxide synthase in the pathogenesis of a rat model of hepatopulmonary syndrome. Gastroenterology 1997; 113:606-614
194. Lockwood AH, Yap EW, Rhoades HM, Wong WH. Altered cerebral blood flow and glucose metabolism in patients with liver disease and minimal encephalopathy. J Cereb Blood Flow Metab 1991;11:331-336
195. Aggarawal S, Kramer D, Yonas H, et al. Cerebral hemodynamic and metabolic changes in fulminant hepatic failure: A retrospective study. Hepatology 1994;19:80-87
196. Srivasta A, Mehta R, Gottstein J, Blei AT. Cerebral blood flow and the hyperdynamic circulation or rats after portocaval anastomosis. J Hepatol 1993;17:15-19
197. Raij L, Baylis C. Glomerular actions of nitric oxide [Editorial]. Kidney Int 1995;48:20-32
198. Bech JN, Nielsen CB, Pedersen EB. Effects of systemic NO synthesis inhibition of RPF, GFR, UNa and vasoactive hormones in healthy humans. Am J Physiol 1996;270:F845-F851
199. Ros J, Claria J, Jimenez W, et al. Role of nitric oxide and prostacyclin in the control of renal perfusion in experimental cirrhosis. Hepatology 1995;22:915-920
200. Atucha NM, Garcia-Estan J, Ramirez A, Perez MC, Quesada T, Romero JC. Renal effects of nitric oxide synthesis inhibition in cirrhotic rats. Am J Physiol 1994;267:R1454-R1460
201. Garcia-Estan J, Atucha NM, Sabio JM, Vargas F, Quesada T, Romero JC. Increased endothelium-dependent renal vasodilation in cirrhotic rats. Am J Physiol 1994;267:R549-R553